Insitro
The AI engine Fit Assessment
BetaInsitro effectively utilizes machine learning to discover patterns and expand therapeutics, optimizing the drug discovery process.
Blurb
Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.
HQ Location
South San Francisco (United States)
Founded
2018
Employees
51 - 200
Total funding raised
$643.00M
Last Funding Event
Series C, $400.00M, March 15, 2021
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Repurposing
- Drug Discovery Optimization
Operator of a data-driven drug discovery and development company intended to transform how drugs are discovered and delivered to patients. The company uses machine learning and high-throughput biology to create massive data sets to be brought to bear on key bottlenecks in pharmaceutical R&D, enabling drug development companies to have predictive models that are used to accelerate target selection, design, and develop effective therapeutics, and to inform clinical strategy.